Progressive Oncological Surgery Is Associated with Increased Curative Resection Rates and Improved Survival in Metastatic Colorectal Cancer
Authors:
- Florian PrimavesiFPFlorian Primavesi
- Stefan StättnerSSStefan Stättner
- Tarkan JägerTJTarkan Jäger
- Georg GöbelGGGeorg Göbel
- Jaroslav PreslJPJaroslav Presl
- Katerina TomanováKTKaterina Tomanová
- Selina BuchnerSBSelina Buchner
- Manuel MaglioneManuel Maglione
- Thomas ReschTRThomas Resch
- Jörg HutterJHJörg Hutter
- Dietmar ÖfnerDietmar Öfner
- Adam DinnewitzerADAdam Dinnewitzer
Open Access
Abstract
Background: Secondary resection rates in first-line chemotherapy trials for metastatic colorectal cancer (mCRC) remain below 15%, representing a clear contrast to reports by specialised surgical centres, where progressive liver, peritoneal-surface, and pulmonary surgery increased access to curative-intent treatment. We present a long-term evaluation of oncosurgical management in a single-centre, analysing the aggregate effect of gradual implementation of surgical subspecialties and systemic treatments on mCRC patients’ resection rates and prognosis. Methods: Patients with newly diagnosed mCRC from 2003 to 2014 were retrospectively categorised into palliative treatment (PAT) and curative intent surgery (CIS) and three time periods were analysed for treatment changes and factors associated with survival. Results: Four hundred-twenty patients were treated (PAT:250/CIS:170). Over time periods, the number of presenting patients remained consistent, whereas curative resection rates increased from 29% to 55%, facilitated by an increment of patients undergoing hepatectomy (21 to 35%), pulmonary surgery (6 to 17%), and peritonectomy/intraoperative chemotherapy (0 to 8%). Also, recently, significantly more multi-line systemic treatments were applied. The median survival markedly improved from 21.9 months (2003–2006; 95% confidence interval (CI) 17.3–26.5) to 36.5 months (2011–2014; 95% CI 26.6–46.4; p = 0.018). PAT was a significant factor of poor survival and diagnosis of mCRC in the latest time period was independently associated with a distinctly lower risk for palliative treatment (odds ratio 0.15). Conclusions: In modern eras of medical oncology, achieving appropriate resection rates through utilization of state-of-the-art oncological surgery by dedicated experts represents a cornerstone for long-term survival in mCRC.Keywords
This publication has 55 references indexed in Scilit:
- Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancerAnnals of Oncology, 2013
- A standard definition of major hepatectomy: resection of four or more liver segmentsHPB, 2011
- Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based studyGut, 2010
- Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trialThe Lancet Oncology, 2010
- Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved ChemotherapyJournal of Clinical Oncology, 2009
- Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)Journal of Clinical Oncology, 2008
- Significant improvement in survival of patients presenting with metastatic colon cancer in the south of The Netherlands from 1990 to 2004Annals of Oncology, 2008
- Survival of patients with colorectal cancer in Austria by sex, age, and stageWiener Medizinische Wochenschrift, 2006
- Classification of Surgical ComplicationsAnnals of Surgery, 2004
- Simultaneous Liver and Colorectal Resections Are Safe for Synchronous Colorectal Liver MetastasisJournal of the American College of Surgeons, 2003